Literature DB >> 25485714

Partial volume correction in quantitative amyloid imaging.

Yi Su1, Tyler M Blazey2, Abraham Z Snyder3, Marcus E Raichle2, Daniel S Marcus2, Beau M Ances3, Randall J Bateman4, Nigel J Cairns5, Patricia Aldea2, Lisa Cash2, Jon J Christensen2, Karl Friedrichsen2, Russ C Hornbeck2, Angela M Farrar2, Christopher J Owen2, Richard Mayeux6, Adam M Brickman6, William Klunk7, Julie C Price8, Paul M Thompson9, Bernadino Ghetti10, Andrew J Saykin11, Reisa A Sperling12, Keith A Johnson13, Peter R Schofield14, Virginia Buckles4, John C Morris4, Tammie L S Benzinger2.   

Abstract

Amyloid imaging is a valuable tool for research and diagnosis in dementing disorders. As positron emission tomography (PET) scanners have limited spatial resolution, measured signals are distorted by partial volume effects. Various techniques have been proposed for correcting partial volume effects, but there is no consensus as to whether these techniques are necessary in amyloid imaging, and, if so, how they should be implemented. We evaluated a two-component partial volume correction technique and a regional spread function technique using both simulated and human Pittsburgh compound B (PiB) PET imaging data. Both correction techniques compensated for partial volume effects and yielded improved detection of subtle changes in PiB retention. However, the regional spread function technique was more accurate in application to simulated data. Because PiB retention estimates depend on the correction technique, standardization is necessary to compare results across groups. Partial volume correction has sometimes been avoided because it increases the sensitivity to inaccuracy in image registration and segmentation. However, our results indicate that appropriate PVC may enhance our ability to detect changes in amyloid deposition.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloid imaging; PET; Partial volume correction; PiB

Mesh:

Substances:

Year:  2014        PMID: 25485714      PMCID: PMC4300252          DOI: 10.1016/j.neuroimage.2014.11.058

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  45 in total

Review 1.  Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

Authors:  Clifford R Jack; Matt A Bernstein; Bret J Borowski; Jeffrey L Gunter; Nick C Fox; Paul M Thompson; Norbert Schuff; Gunnar Krueger; Ronald J Killiany; Charles S Decarli; Anders M Dale; Owen W Carmichael; Duygu Tosun; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

4.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

5.  Registration of [18F]FDG microPET and small-animal MRI.

Authors:  Douglas J Rowland; Joel R Garbow; Richard Laforest; Abraham Z Snyder
Journal:  Nucl Med Biol       Date:  2005-08       Impact factor: 2.408

6.  Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.

Authors:  John C Morris; Paul S Aisen; Randall J Bateman; Tammie L S Benzinger; Nigel J Cairns; Anne M Fagan; Bernardino Ghetti; Alison M Goate; David M Holtzman; William E Klunk; Eric McDade; Daniel S Marcus; Ralph N Martins; Colin L Masters; Richard Mayeux; Angela Oliver; Kimberly Quaid; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Natalie J Selsor; Reisa A Sperling; Michael W Weiner; Chengjie Xiong; Krista L Moulder; Virginia D Buckles
Journal:  Clin Investig (Lond)       Date:  2012-10-01

7.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

8.  Alzheimer's disease therapeutic research: the path forward.

Authors:  Paul S Aisen
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

9.  Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method.

Authors:  Euitae Kim; Miho Shidahara; Charalampos Tsoumpas; Colm J McGinnity; Jun Soo Kwon; Oliver D Howes; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2013-03-13       Impact factor: 6.200

10.  Quantitative analysis of PiB-PET with FreeSurfer ROIs.

Authors:  Yi Su; Gina M D'Angelo; Andrei G Vlassenko; Gongfu Zhou; Abraham Z Snyder; Daniel S Marcus; Tyler M Blazey; Jon J Christensen; Shivangi Vora; John C Morris; Mark A Mintun; Tammie L S Benzinger
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  111 in total

1.  Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.

Authors:  Jeffrey L Dage; Alexandra M V Wennberg; David C Airey; Clinton E Hagen; David S Knopman; Mary M Machulda; Rosebud O Roberts; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2016-07-18       Impact factor: 21.566

2.  Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.

Authors:  Andrei G Vlassenko; Lena McCue; Mateusz S Jasielec; Yi Su; Brian A Gordon; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; John C Morris; Anne M Fagan
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

3.  Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept.

Authors:  Ganesh M Babulal; Ann Johnson; Anne M Fagan; John C Morris; Catherine M Roe
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

4.  Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations.

Authors:  Pratishtha Chatterjee; Anne M Fagan; Chengjie Xiong; Matthew McKay; Atul Bhatnagar; Yunqi Wu; Abhay K Singh; Kevin Taddei; Ian Martins; Samantha L Gardener; Mark P Molloy; Gerhard Multhaup; Colin L Masters; Peter R Schofield; Tammie L S Benzinger; John C Morris; Randall J Bateman; Steven M Greenberg; Marieke J H Wermer; Mark A van Buchem; Hamid R Sohrabi; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

5.  Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Authors:  Suzanne E Schindler; Courtney L Sutphen; Charlotte Teunissen; Lena M McCue; John C Morris; David M Holtzman; Sandra D Mulder; Philip Scheltens; Chengjie Xiong; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2017-07-12       Impact factor: 21.566

6.  Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Authors:  Ganesh M Babulal; Suzie Chen; Monique M Williams; Jean-Francois Trani; Parul Bakhshi; Grace L Chao; Sarah H Stout; Anne M Fagan; Tammie L S Benzinger; David M Holtzman; John C Morris; Catherine M Roe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease.

Authors:  Andrei G Vlassenko; Brian A Gordon; Manu S Goyal; Yi Su; Tyler M Blazey; Tony J Durbin; Lars E Couture; Jon J Christensen; Hussain Jafri; John C Morris; Marcus E Raichle; Tammie L-S Benzinger
Journal:  Neurobiol Aging       Date:  2018-03-20       Impact factor: 4.673

8.  Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.

Authors:  Belinda M Brown; Hamid R Sohrabi; Kevin Taddei; Samantha L Gardener; Stephanie R Rainey-Smith; Jeremiah J Peiffer; Chengjie Xiong; Anne M Fagan; Tammie Benzinger; Virginia Buckles; Kirk I Erickson; Roger Clarnette; Tejal Shah; Colin L Masters; Michael Weiner; Nigel Cairns; Martin Rossor; Neill R Graff-Radford; Stephen Salloway; Jonathan Vöglein; Christoph Laske; James Noble; Peter R Schofield; Randall J Bateman; John C Morris; Ralph N Martins
Journal:  Alzheimers Dement       Date:  2017-05-11       Impact factor: 21.566

9.  BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Authors:  Yen Ying Lim; Jason Hassenstab; Carlos Cruchaga; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Paul Maruff; Peter J Snyder; Colin L Masters; Ricardo Allegri; Jasmeer Chhatwal; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Johannes Levin; Eric McDade; John M Ringman; Martin Rossor; Stephen Salloway; Peter R Schofield; David M Holtzman; John C Morris; Randall J Bateman
Journal:  Brain       Date:  2016-08-12       Impact factor: 13.501

10.  Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.

Authors:  Adam P Mecca; Nicole M Barcelos; Shuo Wang; Anna Brück; Nabeel Nabulsi; Beata Planeta-Wilson; Jennifer Nadelmann; Amanda L Benincasa; Jim Ropchan; Yiyun Huang; Joel Gelernter; Peter H Van Ness; Richard E Carson; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2017-10-06       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.